{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:39Z","timestamp":1790788719799,"version":"4.1.0"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Central nervous system lymphoma (CNSL) is a rare and aggressive malignancy that primarily affects the brain, spinal cord, and meninges. This article provides a comprehensive overview of the current understanding of CNSL encompassing its epidemiology, pathophysiology, clinical presentation, diagnosis, treatment modalities, and prognosis. Although the main focus is on primary CNS lymphoma (PCNSL), ocular lymphoma, primary leptomeningeal lymphoma, and secondary CNS lymphoma are also discussed. The pathobiology of CNSL involves the infiltration of malignant lymphocytes within the CNS parenchyma or leptomeninges. Various risk factors and immunological mechanisms contribute to its development, including immunodeficiency states, chronic inflammation, and genomic alterations. Accurate diagnosis is crucial for appropriate management, given the heterogeneous clinical presentation. The neuroimaging, systemic imaging, and other modalities for diagnosis and evaluation for extent of disease involvement will be discussed. Additionally, the importance of histopathological examination, cerebrospinal fluid (CSF) analysis, and molecular testing in confirming the diagnosis and guiding treatment decisions are highlighted. The treatment landscape for CNSL has evolved significantly. Therapeutic approaches encompass a multimodal strategy combining high-dose methotrexate-based chemotherapy, consolidation with whole-brain radiation therapy, and high-dose chemotherapy with stem cell rescue. Recent advancements in targeted therapies and immunomodulatory agents offer promising avenues for future treatment options. We review the clinical outcomes and prognostic factors influencing the survival of CNSL patients, including age, performance status, disease stage, and genetic abnormalities.<\/jats:p>","DOI":"10.1055\/s-0043-1776783","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T23:54:08Z","timestamp":1700783648000},"page":"825-832","source":"Crossref","is-referenced-by-count":16,"title":["Central Nervous System Lymphoma"],"prefix":"10.1055","volume":"43","author":[{"given":"Trusha","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyshak A.","family":"Venur","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/diagnostics10121076","article-title":"Primary central nervous system lymphomas: a diagnostic overview of key histomorphologic, immunophenotypic, and genetic features","volume":"10","author":"M IS Lauw","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"19","key":"ref2","doi-asserted-by":"crossref","first-page":"31254","DOI":"10.18632\/oncotarget.16115","article-title":"Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma","volume":"8","author":"S Ruggieri","year":"2017","journal-title":"Oncotarget"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrneurol.2013.83","article-title":"Diagnosis and treatment of primary CNS lymphoma","volume":"9","author":"A Korfel","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"21","key":"ref4","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"C Grommes","year":"2017","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref5","first-page":"1476","article-title":"Central nervous system lymphomas","volume":"26","author":"C Grommes","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/WCO.0000000000001115","article-title":"Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies","volume":"35","author":"I Hern\u00e1ndez-Verdin","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10428194.2022.2133541","article-title":"Primary CNS lymphoma: update on molecular pathogenesis and therapy","volume":"64","author":"S S Mo","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood.2020008520","article-title":"EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity","volume":"137","author":"M K Gandhi","year":"2021","journal-title":"Blood"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/neuonc\/1.2.89","article-title":"The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death","volume":"1","author":"P P Moln\u00e1r","year":"1999","journal-title":"Neuro-oncol"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"R F Barajas","year":"2021","journal-title":"Neuro-oncol"},{"issue":"17","key":"ref11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/01.wnl.0000327672.04729.8c","article-title":"Primary CNS lymphoma with intraocular involvement: international PCNSL Collaborative Group Report","volume":"71","author":"S A Grimm","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2005.07.109","article-title":"Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group","volume":"23","author":"T N Shenkier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamaneurol.2013.606","article-title":"A systematic approach to the diagnosis of suspected central nervous system lymphoma","volume":"70","author":"B J Scott","year":"2013","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study","volume":"193","author":"A JM Ferreri","year":"2021","journal-title":"Br J Haematol"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"L E Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"C P Fox","year":"2019","journal-title":"Br J Haematol"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"L R Schaff","year":"2022","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1515\/tnsci-2020-0005","article-title":"A case of primary central nervous system lymphoma mimic neuromyelitis optica","volume":"11","author":"X Sheng","year":"2020","journal-title":"Transl Neurosci"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","article-title":"Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium","volume":"16","author":"C C Chan","year":"2011","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.25259\/JCIS_135_2021","article-title":"Different facets of intracranial central nervous system lymphoma and its imaging mimics","volume":"12","author":"H M Kwok","year":"2022","journal-title":"J Clin Imaging Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1752-1947-4-5","article-title":"Neurolymphomatosis mimicking neurosarcoidosis: a case report","volume":"4","author":"E Santos","year":"2010","journal-title":"J Med Case Rep"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"A J Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"36","key":"ref23","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"L E Abrey","year":"2006","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"J J Zhu","year":"2009","journal-title":"Neuro-oncol"},{"issue":"25","key":"ref25","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"J L Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"A Omuro","year":"2015","journal-title":"Blood"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"A JM Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2021.1074","article-title":"Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant","volume":"7","author":"M Scordo","year":"2021","journal-title":"JAMA Oncol"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"C Grommes","year":"2019","journal-title":"Blood"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)\u2020","volume":"30","author":"H Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"23","key":"ref31","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"L Nayak","year":"2017","journal-title":"Blood"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/09273940903108544","article-title":"Primary intraocular lymphoma: diagnosis and differential diagnosis","volume":"17","author":"H N Sen","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1212\/WNL.41.1.95","article-title":"Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature","volume":"41","author":"D H Lachance","year":"1991","journal-title":"Neurology"},{"issue":"19","key":"ref34","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1212\/01.wnl.0000435302.02895.f3","article-title":"Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report","volume":"81","author":"J W Taylor","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s11864-022-01017-4","article-title":"Secondary central nervous system lymphoma: updates in treatment and prophylaxis strategies","volume":"23","author":"V Orellana-Noia","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"03","key":"ref36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"S Bobillo","year":"2023","journal-title":"Haematologica"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1776783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T23:37:51Z","timestamp":1702597071000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1776783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":36,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2023,12,14]]},"published-print":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1776783","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}